Trials / NCT07266584
Restoration of Central Vision With PRIMA in Patients With Photoreceptor Degeneration
Recruiting now N/A Retinal implant
- Sponsor
- Science Corporation
- Treatment
- PRIMA Products
- Gene
- Not stated
- Conditions
- Stargardt Disease, Retinitis Pigmentosa (RP), Inherited Retinal Degeneration
- Ages
- 18 Years to no upper limit
- Enrollment
- 5 participants
- Started
- 2026-04-22
- Main results expected
- 2029-03-01
- Results posted
- Not yet
- Record last updated
- 2026-08-17
What the study is testing
The objective of this study is to evaluate the efficacy and safety of the PRIMA Products in participants with inherited retinal degeneration affecting the macula (including but not limited to Stargardt disease, and Retinitis Pigmentosa).
Eligible participants will be implanted with the PRIMA Stim implant. The participants will be assessed with various visual function and functional vision tests at defined timepoints throughout the clinical investigation with the PRIMA Products. The purpose of this study is to gather enough clinical data to support the clinical evaluation required for the continuous development to improve the PRIMA Products.
Where it runs
Australia (1)
- Sydney Eye Hospital, Sydney, New South Wales (recruiting now)